NeuroSense Therapeutics, Inc. is a clinical-stage neuroscience company focused on developing innovative treatments and diagnostic tools for central nervous system (CNS) disorders. Founded in 2018 and headquartered in Tel Aviv, Israel, NeuroSense combines advanced biomarker technology with emerging therapeutic approaches to address conditions such as post-traumatic stress disorder (PTSD), major depressive disorder (MDD) and other neuropsychiatric illnesses. The company’s platform leverages electroencephalography (EEG) and machine learning algorithms to identify and track neural signatures that may predict treatment response and disease progression.
Central to NeuroSense’s pipeline is its efforts to optimize and monitor psychedelic-assisted therapies. Drawing on historical research in psychedelics and modern clinical protocols, the company conducts controlled clinical trials investigating compounds such as psilocybin and MDMA. By integrating EEG-based biomarkers with standardized therapy sessions, NeuroSense aims to personalize treatment regimens, improve efficacy, and reduce the risk of adverse effects. In parallel, the company is developing digital tools and software applications to support remote monitoring and data analytics, enabling clinicians to make data-driven decisions throughout the course of treatment.
NeuroSense serves patients and academic partners across North America, Europe and Israel, collaborating with leading research institutions and medical centers to advance its clinical programs. The company’s multidisciplinary leadership team includes experts in neuroscience, psychiatry, bioengineering and regulatory affairs. Chief Executive Officer Dr. Ronen Durst, a neuroscientist with extensive experience in neurodiagnostics and biomarker development, leads NeuroSense’s strategic vision. The company’s advisory board features prominent clinicians and researchers who guide trial design, regulatory strategy and novel applications of neurotechnology.
With its integrated approach to diagnostics and therapeutics, NeuroSense Therapeutics is positioned at the forefront of personalized mental health care. By harnessing objective neural measures alongside innovative treatment modalities, the company seeks to transform the standard of care for patients with treatment-resistant neuropsychiatric disorders and to unlock new pathways for recovery and long-term wellbeing.
AI Generated. May Contain Errors.
Free NRSN Stock Alerts